Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/22/2009

atent or application and, generally, 10 years after the first commercial sale of any product licensed under the agreement. Wyeth may terminate the agreement without cause at any time upon 90 days' written notice.

Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1 / 2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the Company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Sec
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
3. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... an alcohol-based hand sanitizer, asks food processors and food ... the hand sanitizer they’re currently using to Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... Sanitizers believes there are key criteria that make a ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Fla. Exciting new work by a Florida State ... system that can take your temperature, emit white light, ... And, the molecule looks like a butterfly. , Biwu ... Biomedical Engineering in the FAMU-FSU College of Engineering, created ... but has continued to discover that his creation has ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... is offering a promotion for Eppendorf Safe ... customers to purchase the highest quality tubes at ... are ideal for customers doing chemical, medical, pharmaceutical, ... technicians who are not regularly able to afford ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Driven by the human genome project, and research in the ... antibacterial, antifungal, and genetic therapeutics), world market for biotechnology reagents ... towards proteomics from genomics in the post-genome-project research period is ... years. , ...
... Nov. 12 Melbourne-based Starfish,Ventures announced today the ... $185 million, the largest venture capital fundraising in,Australia. ... and Cleantech,companies., The success of this fundraising ... of Australia,s ability to foster the development of,innovative ...
... Nov. 12 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) ... Graham as the Company,s Chief Executive Officer and as ... had been serving as,the Company,s acting Chief Executive Officer ... impressive job as acting CEO in managing the transition,of ...
Cached Biology Technology:World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 2World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 3Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund 2TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors 2TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors 3
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
(Date:8/28/2014)... 28, 2014A new method for measuring and imaging how ... and researchers better understand how drug abuse affects the ... tissue engineering, and lead to better treatment options for ... team of researchers from Stony Brook University in New ... was published today in The Optical Society,s (OSA) open-access ...
(Date:8/28/2014)... significant health risk to people with asthma according to a ... Clinical Immunology . , By critically reviewing the findings from ... that the presence of several types of mould can lead ... the likelihood of developing the condition. , The research has ... Medical School and is the first time all of the ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... Missouri-Columbia has discovered a way to create engineered minichromosomes ... discovery opens new possibilities for the development of crops ... and herbicides, and for the development of proteins and ... , In a paper published in the Proceedings of ...
... In the daunting marathon that leads to successful ... before entering clinical trials. Researchers from Massachusetts Institute ... cell culture test for assessing a compound's genetic ... animal tests. This assay would allow genetic toxicity ...
... to rapid genetic adaptations in the nematode Acrobeloides ... and lay more eggs under polluted conditions than ... Doroszuk demonstrated this in her study into the ... , Environmental pollution is an important cause ...
Cached Biology News:Researchers attach genes to minichromosomes in maize 2DNA-damage test could aid drug development 2DNA-damage test could aid drug development 3Asexual worm quickly adapts to soil contamination 2
... Phosphate Assay Kit is based on quantification ... Green, molybdate and free orthophosphate. The rapid ... conveniently measured on a spectrophotometer (600-660 nm) ... colorimetric assay kits have been optimized to ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
...
Biology Products: